Comparative Pharmacology
Head-to-head clinical analysis: EDARBYCLOR versus TEVETEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EDARBYCLOR versus TEVETEN.
EDARBYCLOR vs TEVETEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
EDARBYCLOR is a fixed-dose combination of azilsartan medoxomil, an angiotensin II receptor blocker (ARB), and chlorthalidone, a thiazide-like diuretic. Azilsartan selectively blocks AT1 receptors, reducing angiotensin II-mediated vasoconstriction, aldosterone secretion, and renal sodium reabsorption. Chlorthalidone inhibits sodium-chloride cotransport in the distal convoluted tubule, increasing excretion of sodium, chloride, and water, thereby reducing plasma volume.
Selective angiotensin II receptor type 1 (AT1) antagonist, blocking the vasoconstrictor and aldosterone-secreting effects of angiotensin II.
One tablet (azilsartan medoxomil 40 mg / chlorthalidone 12.5 mg or 40 mg / 25 mg) orally once daily.
400-800 mg orally once daily; can be divided twice daily if needed for adequate blood pressure control.
None Documented
None Documented
Terminal elimination half-life is approximately 11-12 hours for azilsartan medoxomil; clinical consequence: supports once-daily dosing for 24-hour blood pressure control
Terminal elimination half-life is approximately 7-8 hours in patients with normal renal function, supporting once-daily dosing.
Renal (approximately 60% as unchanged drug and metabolites), biliary/fecal (approximately 40%)
Renal (approximately 60% as unchanged drug) and biliary/fecal (approximately 40%).
Category C
Category C
Angiotensin II Receptor Blocker/Thiazide Diuretic Combination
Angiotensin II Receptor Blocker